- Trial phase
- Approved
- Time to market
- Already approved and marketed since November 2018. Full first-line approval granted January 2026.
- Why 3/10
- Lorbrena is already approved and marketed with no pending PDUFA, pivotal readout, or Advisory Committee in the next ~12 months. The next hard catalyst would be a ruling in the Sun Pharma patent lawsuit (filed Oct 2026), but that has no set date. As an approved drug at a mega-cap company, impactScore defaults to 3.
Lorbrena has no near-term binary catalyst. The next event to watch is the Sun Pharma patent litigation (filed Oct 2026 in Delaware), where a ruling could affect generic entry timing. Separately, watch for any label expansion into ROS1-positive NSCLC or pediatric indications. For Pfizer as a whole, Q3 2026 earnings (just reported Nov 3) and the 2027 revenue outlook are far more material than Lorbrena-specific news.
Price Chart
Executive Summary
Lorbrena (lorlatinib) is Pfizer's third-generation ALK inhibitor for ALK-positive metastatic non-small cell lung cancer. Originally approved in November 2018 under accelerated approval, the FDA expanded it to full first-line approval in January 2026 based on the Phase 3 CROWN trial. Seven-year CROWN data presented at ASCO 2026 showed 55% of patients alive without progression at 7 years, with median progression-free survival still not reached. Lorbrena is a growing but small part of Pfizer's $62.6B revenue base. Pfizer is defending its patent estate (compound patent to March 2033) against a Sun Pharma generic challenge filed in October 2026. The drug has no near-term binary catalyst, making it a low-impact asset for Pfizer's stock.
How It Works
Lorbrena is a pill that blocks a specific cancer-driving protein called ALK (anaplastic lymphoma kinase). About 3-5% of non-small cell lung cancers have a mutation that keeps ALK switched on, making cancer cells grow. Lorbrena is a third-generation drug designed to be more potent than earlier ALK blockers and to penetrate the brain, where lung cancer often spreads. It also blocks a related protein called ROS1.
Trial Status
The pivotal Phase 3 CROWN trial (NCT03052608) comparing Lorbrena to crizotinib in first-line ALK+ advanced NSCLC has completed enrollment. Seven-year follow-up data were presented at ASCO 2026 (May 29, 2026), showing median PFS not yet reached and a 55% progression-free survival rate at 7 years. The trial continues for long-term follow-up.
The Two-Sided Case
Upcoming Catalysts
- Patent litigation against Sun Pharma (filed Oct 1, 2026 in Delaware District Court) - any ruling on generic ANDA could affect Lorbrena's market exclusivity timeline.
- Potential label expansion into ROS1-positive NSCLC or pediatric ALK-positive glioma (a prior authorization document suggests pediatric glioma exploration).
- CROWN trial further long-term follow-up data at future medical meetings.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report